Myomo Expands Distribution via Ottobock Care, but Cash Burn and ICFR Risks Persist

What happened

Myomo announced that its MyoPro powered arm brace will be available through Ottobock Care clinics nationwide, expanding access for patients with upper extremity impairment. This distribution agreement leverages Ottobock's established orthotics and prosthetics network, potentially accelerating adoption and order flow. However, the DeepValue master report flags that the company's investment case still hinges on proving sustainable unit economics and cash discipline, with a net loss of $6.2M in 2024 and operating cash outflow accelerating to ~$11.5M in 1H25 against only ~$15.5M in liquidity. The expansion does not directly address the material weakness in internal controls over financial reporting (ICFR) or the risk of future dilution given the constrained runway. While the Ottobock partnership is a positive step for distribution breadth, it does not alter the fundamental near-term risks of cash burn and reimbursement execution.

Implication

For the long-term thesis, the Ottobock partnership is a building block for scaling distribution, but the company must convert this into consistent revenue growth and positive cash conversion. Investors should monitor claim approval rates, audit outcomes, and working capital trends; if the expansion drives materially higher cash-burning volume without improving unit economics, it could exacerbate dilution risk.

Thesis delta

The Ottobock Care expansion modestly strengthens Myomo's distribution channel and could support revenue growth, but it does not change the core investment thesis. The DeepValue report's HOLD/NEUTRAL stance remains appropriate, as the partnership does not alleviate the primary risks of cash burn, ICFR shortcomings, and uncertain payer fee sufficiency. We see no reason to adjust the watch items or trigger points based on this news alone.